Alyssa Spiegel
Medical · Dallas, TXNPI 1003126061
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 907 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 907 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$2K
- Sun Pharmaceutical Industries Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- LEO Pharma Inc.$1K
- Sanofi$1K
- plus $7K from 25 others
What the payments were for
- Food & beverage$17,02097%
- Education$5733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 208 | $3,997 |
| Johnson & Johnson | 93 | $1,692 |
| Sun Pharmaceutical Industries Inc. | 64 | $1,621 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,197 |
| LEO Pharma Inc. | 53 | $1,186 |
| Sanofi | 40 | $1,002 |
| Novartis | 46 | $940 |
| Lilly USA, LLC | 43 | $838 |
| Arcutis Biotherapeutics, Inc. | 76 | $759 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 33 | $619 |
| E.r. Squibb & Sons, L.L.C. | 28 | $555 |
| Galderma Laboratories, L.p. | 36 | $547 |
| Incyte Corporation | 30 | $537 |
| Amgen | 21 | $483 |
| UCB, Inc. | 15 | $308 |
| Pfizer | 14 | $257 |
| Dermavant Sciences, Inc. | 16 | $167 |
| Mayne Pharma Commercial LLC | 9 | $147 |
| Almirall LLC | 6 | $110 |
| Boehringer Ingelheim | 4 | $102 |
| Botanix SB Inc | 5 | $91 |
| Helsinn Therapeutics (U.S.), Inc. | 5 | $81 |
| Revance Therapeutics, Inc. | 1 | $79 |
| Journey Medical Corporation | 5 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Biofrontera Inc. | 2 | $33 |
| Genentech USA, Inc. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $20 |
| EPI Health, LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$135
How this compares
$17,593 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $47,407 |
| Clobetasol Propionate | 19 | $1,131 |
| Metronidazole | 17 | $890 |
| ValacyclovirValacyclovir Hcl | 29 | $741 |
| Doxycycline Hyclate | 38 | $709 |
| Ketoconazole | 29 | $589 |
| Betamethasone Dipropionate | 13 | $548 |
| Triamcinolone Acetonide | 49 | $510 |
| Mupirocin | 45 | $312 |
| Hydrocortisone | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.